http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#Head http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#assertion http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#provenance http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#pubinfo http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#assertion http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object https://identifiers.org/MONDO:0005086 http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/PUBCHEM.COMPOUND:9823820 http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#association http://www.w3.org/2000/01/rdf-schema#label lenvima is a kinase inhibitor that is indicated for the treatment of patients with locally recurrent or metastatic progressive radioactive iodine refractory differentiated thyroid cancer dtc 1 1 in combination with everolimus for the treatment of patients with advanced renal cell carcinoma rcc following one prior anti angiogenic therapy 1 2 for the first line treatment of patients with unresectable hepatocellular carcinoma hcc 1 3 lenvima is indicated for the treatment of patients with locally recurrent or metastatic progressive radioactive iodine refractory differentiated thyroid cancer dtc lenvima is indicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma rcc following one prior anti angiogenic therapy lenvima is indicated for the first line treatment of patients with unresectable hepatocellular carcinoma hcc http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/MONDO:0005086 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease https://identifiers.org/PUBCHEM.COMPOUND:9823820 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#provenance http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#pubinfo http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#sig http://purl.org/nanopub/x/hasSignature Ezal1yShsdnUhXEdC18GfpnE+yHuPlwTyuABdgUVHVto70HYiXHROyx4dJpUEmMzAiqTtbpwWw7h2+dZXsXFfbi5VqsniqoP0EkqAqcqeb2zZ1THzvHennGbjdZ2Vrx/XE5XgLgBIvoVL29cej/vNUGURpQvqIydw9ISZREkDs8= http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A http://purl.org/dc/terms/created 2021-06-08T21:07:15.752+02:00 http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs